Comparative Pharmacology
Head-to-head clinical analysis: OLMESARTAN MEDOXOMIL versus TEVETEN HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OLMESARTAN MEDOXOMIL versus TEVETEN HCT.
OLMESARTAN MEDOXOMIL vs TEVETEN HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to decreased peripheral vascular resistance and reduced blood pressure.
TEVETEN HCT combines eprosartan mesylate, an angiotensin II receptor antagonist, and hydrochlorothiazide, a thiazide diuretic. Eprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
20 mg orally once daily, titrate as needed to 40 mg once daily; maximum 40 mg daily.
One tablet orally once daily, containing eprosartan 600 mg and hydrochlorothiazide 12.5 mg or 25 mg, with or without food. Maximum dose: eprosartan 600 mg/hydrochlorothiazide 25 mg per day.
None Documented
None Documented
Terminal elimination half-life: 10-15 hours; reaches steady-state after 3-5 days; clinically allows once-daily dosing.
Eprosartan: 5-9 hours; Hydrochlorothiazide: 6-15 hours; allows once-daily dosing.
Renal: 35-50% as unchanged drug; biliary/fecal: 50-65% via bile into feces, primarily as parent drug.
Eprosartan: renal (70% unchanged, 10% as metabolite), biliary/fecal (20%); Hydrochlorothiazide: renal (≥95% unchanged).
Category D/X
Category C
ARB
ARB + Thiazide Diuretic Combination